Contact
Advancing the Treatment of Glioblastoma and Basel Cell Carcinoma
Princeton Oncotherapeutics, Inc., located in Princeton, NJ, is developing new treatments for glioblastoma and basal cell carcinoma. Princeton Oncotherapeutics’s D-85 is a membrane-disruptive metabolic agent that induces dose-responsive rapid reactive oxygen species (ROS) generation and metabolic cell collapse.
2D cell line assays show significant cytotoxicity for glioblastoma cell lines U251 and TMZ-unresponsive T98G. Unique delivery systems are in development prior to PDX assays.
NADPH
D85 targets NADPH (Nicotinamide adenine dinucleotide phosphate reduced). NADPH is a dinucleotide upregulated in all cancer cells to permit their rapid metabolism and reproduction, and ROS recovery. Selective suppression of the ligands on NADPH in GBM and BCC cancer cells results in both ETC disruption and inhibition of ROS recovery.
SCIENCE
Glioblastoma
The NCI 60-cell line assay and in-house studies support proof of concept in several GBM cell lines.
Princeton Oncotherapeutic’s 2D assays using D85 suppress both methylated and unmethylated GBM cell lines.
Research focus and goal: Approval of a CED intra-tumoral first line treatment to shrink or eradicate all types of GBM tumors and reduce/halt local recurrence, alone or in combination with current therapies.
Basal Cell Carcinoma
NADPH inhibition is also an effective target for the topical treatment of basal cell carcinoma (BCC). D-85 offers a potentially high cure rate without surgical scarring or a high reimbursement cost. Mohs surgery usually requires deep incisions.
Mohs micrographic surgery, the current Standard of Care for BCC, is highly effective vs. standard excision and current topicals, but can leave deformities and scars on sensitive areas such as the face, nose, ears and lips.
Anecdotal evidence suggests that BCC could be treated with D85, alone or in combination with Imiquimod.
Research focus and goal: Demonstrate safety and seek FDA approval under the 505b2 pathway for the topical treatment of all types of BCC, alone or in combination with current standards of care, including Mohs.
Our Mission: Advancement of Oncotherapies for BCC and Glioblastoma
Princeton Oncotherapeutics believes that BCC, the most common form of skin cancer, can be managed at both its early and more advanced stages with topical home care that is non-inflammatory and painless. We are also seeking investors and industry partners to utilize more sophisticated delivery vehicles for the control and possible cure of GBM, in both adjuvant and first line formulations.
Affiliated Research Organizations
Acknowledgements
